This report was first published by Endpoints News. To see the original version, click here
Eli Lilly is returning to South Korea for another deal worth more than $1 billion.
The Indianapolis pharma giant is teaming up with ABL Bio, which already has partnerships with GSK, Sanofi, NovaBridge Biosciences, Compass Therapeutics and others.
您已閱讀18%（335字），剩余82%（1556字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。